The emerging role of targeted therapy for hematologic malignancies:: Update on bortezomib and tipifarnib

被引:26
作者
Armand, Jean-Pierre
Burnett, Alan K.
Drach, Johannes
Harousseau, Jean-Luc
Lowenberg, Bob
Miguel, Jesus San
机构
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Natl Inst Canc Res, London, England
[3] Med Univ Vienna, Vienna, Austria
[4] Univ Hosp Nantes, Nantes, France
[5] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[6] Univ Hosp Salamanca, Salamanca, Spain
关键词
bortezomib; multiple myeloma; proteasome inhibition; tipifarnib; targeted therapy;
D O I
10.1634/theoncologist.12-3-281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As therapy for hematologic malignancy evolves, new regimens and novel agents that target specific cellular processes allow a more optimistic prognosis for many patients. Bortezomib and tipifarnib are two new, targeted treatments for hematologic malignancies. Bortezomib, a proteasome inhibitor, has shown impressive efficacy in patients with relapsed multiple myeloma and as initial treatment, including before autologous stem cell transplantation. It has been studied as monotherapy and in combination with standard treatments such as dexamethasone, and with newer agents such as the immunomodulators thalidomide and lenalidomide; response is encouraging, even in patients who have relapsed after previously receiving components of a regimen as single agents. Bortezomib is generally well tolerated, including in combination with novel and conventional agents. Tipifarnib is a specific inhibitor of farnesyltransferase. Clinical trials in patients with high-risk acute leukemias and myelodysplastic syndromes have demonstrated good efficacy with tipifarnib. Continued investigation with these new, targeted treatments will further define their use as treatment options in patients with hematologic cancer.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 69 条
[21]  
Goy A, 2005, J CLIN ONCOL, V23, p575S
[22]   Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma [J].
Goy, A ;
Younes, A ;
McLaughlin, P ;
Pro, B ;
Romaguera, JE ;
Hagemeister, F ;
Fayad, L ;
Dang, NH ;
Samaniego, F ;
Wang, M ;
Broglio, K ;
Samuels, B ;
Gilles, F ;
Sarris, AH ;
Hart, S ;
Trehu, E ;
Schenkein, D ;
Cabanillas, F ;
Rodriguez, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :667-675
[23]   Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Premilinary results of an IFM phase II study [J].
Harousseau, JL ;
Attal, M ;
Coiteux, V ;
Stoppa, AM ;
Hulin, C ;
Benboubker, L ;
Fuzibet, JG ;
Renard, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :598S-598S
[24]   New targets for therapy in breast cancer - Farnesyltransferase inhibitors [J].
Head, J ;
Johnston, SRD .
BREAST CANCER RESEARCH, 2004, 6 (06) :262-268
[25]  
Hideshima T, 2001, CANCER RES, V61, P3071
[26]   p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells [J].
Hideshima, T ;
Podar, K ;
Chauhan, D ;
Ishitsuka, K ;
Mitsiades, C ;
Tai, YT ;
Hamasaki, M ;
Raje, N ;
Hideshima, H ;
Schreiner, G ;
Nguyen, AN ;
Navas, T ;
Munshi, NC ;
Richardson, PG ;
Higgins, LS ;
Anderson, KC .
ONCOGENE, 2004, 23 (54) :8766-8776
[27]   Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma [J].
Hideshima, T ;
Chauhan, D ;
Hayashi, T ;
Akiyama, M ;
Mitsiades, N ;
Mitsiades, C ;
Podar, K ;
Munshi, NC ;
Richardson, PG ;
Anderson, KC .
ONCOGENE, 2003, 22 (52) :8386-8393
[28]   Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function [J].
Jagannath, S ;
Barlogie, B ;
Berenson, JR ;
Singhal, S ;
Alexanian, R ;
Srkalovic, G ;
Orlowski, RZ ;
Richardson, PG ;
Anderson, J ;
Nix, D ;
Esseltine, DL ;
Anderson, KC .
CANCER, 2005, 103 (06) :1195-1200
[29]   A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma [J].
Jagannath, S ;
Barlogie, B ;
Berenson, J ;
Siegel, D ;
Irwin, D ;
Richardson, PG ;
Niesvizky, R ;
Alexanian, R ;
Limentani, SA ;
Alsina, M ;
Adams, J ;
Kauffman, M ;
Esseltine, DL ;
Schenkein, DP ;
Anderson, KC .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (02) :165-172
[30]  
JAGANNATH S, 2005, HAEMATOLOGICA S1, V90, pA148